Citi analyst Joanne Wuensch keeps a Buy rating on Boston Scientific (BSX) with a $125 price target after the company announced the discontinuation of global Acurate neo2 and Acurate Prime transcatheter aortic valve replacement valve sales. The decision was made given “recent discussions with regulators, which resulted in increased clinical and regulatory requirements to maintain regulatory approvals in global markets and to obtain approvals in new regions.” Citi says Boston Scientific’s outside the U.S. TAVR revenue reached $214M in 2024, but the company has struggled to bring the product to the U.S., and outside the U.S. sales have weakened after unfavorable Acurate IDE clinical data. The firm views the discontinuation as a “wise move” when thinking about resource management. Boston Scientific still expects to reach Q2 and 2025 reported and organic sales and earnings guidance, Citi points out.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific’s Strategic Shift and Resilient Outlook: A Buy Rating with 17.7% Expected Return
- Boston Scientific’s Strategic Shift and Growth Potential: A Buy Rating Amid Product Discontinuation and Promising Innovations
- Boston Scientific discontinuing worldwide sales of ACURATE Aortic Valve Systems
- Boston Scientific Discontinues Aortic Valve Systems
- Boston Scientific price target raised to $125 from $119 at Citi
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue